Pancreatic and intestinal processing of proglucagon in man

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Diabetologia

• Publication date

  1987-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/BF00274797PMID 3446554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

  1987cited by this paper
• Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

  1987cited by this paper
• Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).

  1987cited by this paper
• Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.

  1986cited by this paper
• Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

  1986cited by this paper
• Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry.

  1985cited by this paper
• Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.

  1985cited by this paper
• Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets

  1985cited by this paper
• Molecular forms of glucagon‐like peptides in man

  1985cited by this paper
• Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon.

  1984influential reference
• Glucagon-related peptides in the human gastrointestinal mucosa

  1984cited by this paper
• Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.

  1984cited by this paper
• How glucagon-like is glucagon-like peptide-1?

  1984cited by this paper
• Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin--current status.

  1983cited by this paper
• Exon duplication and divergence in the human preproglucagon gene

  1983influential reference
• Circulating glucagon after total pancreatectomy in man

  1983cited by this paper
• Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin.

  1982cited by this paper
• Heterogeneity of somatostatin like immunoreactivity (SLI) in extracts of porcine, canine and human pancreas.

  1981cited by this paper
• Preparation of 125I-labeled synthetic porcine secretin for radioimmunoassay.

  1976cited by this paper
• Production and evaluation of glucagon antibodies for radioimmunoassay.

  1974cited by this paper
• THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS

  1949cited by this paper

• Research progress in precision medicine for type 2 diabetes based on the GLP-1

  2026cites this paper
• Oppositely biased glucagon‐like peptide‐1 receptor agonism does not differentially affect lipid metabolism in APOE*3‐Leiden CETP mice

  2025cites this paper
• Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists

  2025cites this paper
• Ectopic fat deposition in intestinal wall caused the increase of L cell pyroptosis mainly through local hypoxia.

  2025cites this paper
• Predictive prioritization of enhancers associated with pancreatic disease risk.

  2025cites this paper
• Predictive Prioritization of Enhancers Associated with Pancreas Disease Risk

  2024cites this paper
• Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

  2024cites this paper
• The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion

  2022cites this paper
• Antinociceptive glucagon-like peptides

  2022cites this paper
• What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?

  2021cites this paper
• Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

  2021cites this paper
• Metabolic Messengers: glucagon-like peptide 1

  2021cites this paper
• Proglucagon-Derived Peptides as Therapeutics

  2021influential citation
• Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis

  2020cites this paper
• Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion

  2020cites this paper
• Selective stimulation of colonic L cells improves metabolic outcomes in mice

  2020cites this paper
• Experience with teduglutide treatment for short bowel syndrome in clinical practice.

  2019cites this paper
• The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship.

  2019cites this paper
• A novel epigenetic mechanism of FXR inhibiting GLP-1 secretion via miR-33 and its downstream targets.

  2019cites this paper
• GLP-1: Molecular mechanisms and outcomes of a complex signaling system.

  2019cites this paper
• Aspartic Acid Forming α-Ketoacid-Hydroxylamine (KAHA) Ligations with (S)-4,4-difluoro-5-oxaproline.

  2019cites this paper
• Extrapancreatic glucagon: Present status.

  2019cites this paper
• Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice.

  2019cites this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cites this paper
• Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications.

  2019cites this paper
• Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial

  2018cites this paper
• Differential engagement of polar networks in the glucagon‐like peptide 1 receptor by endogenous variants of the glucagon‐like peptide 1

  2018cites this paper
• Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function.

  2018cites this paper
• Preparation of the Extracellular Domain of GLP-1 Receptor and Its Interaction with GLP-1

  2017cites this paper
• A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination.

  2017cites this paper
• Persistence of Pancreatic Insulin mRNA Expression and Proinsulin Protein in Type 1 Diabetes Pancreata.

  2017cites this paper
• A 11 Patent Number : 5 , 789 , 379 45 ) Date of Patent : Aug

  2017cites this paper
• Transcriptomic analysis of the differentiating ovary of the protogynous ricefield eel Monopterus albus

  2017cites this paper
• Discovery, characterization, and clinical development of the glucagon-like peptides.

  2017cites this paper
• Impaired Glucose Tolerance in Childhood Obesity Contribution of Glucagon , GLP-1 and Inflammation

  2016cites this paper
• Prevalence, Dietary Pattern, Nutrient Intake and Clinical Profile of Adults Aged Between 30-50 Years Attending Diabetic with Hypertensive Patient, Clinic at Allahabad City. -

  2016cites this paper
• Non‐Insulin Parenteral Therapies

  2016cites this paper
• Differential gestation feeding levels on sow and litter performance, nutrient digestibility and energy homeostasis

  2016cites this paper
• Intra-islet glucagon-like peptide 1.

  2016cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cites this paper
• Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells.

  2016cites this paper
• Is GLP‐1 a hormone: Whether and When?

  2016influential citation
• Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.

  2016cites this paper
• Physiological and pathophysiological control of glucagon secretion by pancreatic α-cells

  2015cites this paper
• Efeito do peptídeo-1 semelhante ao glucagon endógeno sobre a atividade do NHE3 em túbulo proximal renal

  2015cites this paper
• The incretin effect in critically ill patients: a case–control study

  2015cites this paper
• Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives

  2015cites this paper
• Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation

  2014influential citation
• The Parenteral Feedingand Secretionof Regulatory Peptides inInfants

  2014cites this paper
• Glucagon-like peptide-1: glucose homeostasis and beyond.

  2014cites this paper
• Sweet taste receptor expression in ruminant intestine and its activation by artificial sweeteners to regulate glucose absorption.

  2014cites this paper
• Pancreatic Glucagon-Like Peptide 1: What is known?

  2014cites this paper
• Recombinant production of human glucagon-like peptide-1 mutant

  2014cites this paper
• The History of GLP-1 and the Debate Regarding Its Tissue-Specific Expression

  2014cites this paper
• The Parenteral Feeding and Secretion of Regulatory Peptides in Infants

  2014cites this paper
• Glucagon-Like Peptide-1 and Its Implications in Obesity

  2013cites this paper
• The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.

  2013cites this paper
• Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.

  2013cites this paper
• Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP1R activation

  2013influential citation
• Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling

  2013cites this paper
• THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY

  2013cites this paper
• Exocytosis in Type 2 Diabetes- Functional and genetic studies of hormone secretion

  2012cites this paper
• Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.

  2012influential citation
• Anorexigenic effects of GLP-1 and its analogues.

  2012cites this paper
• Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide

  2012cites this paper
• Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

  2012cites this paper
• EW, a novel recombinant analogue of exendin-4 expressed in Escherichia coli

  2011cites this paper
• Production and solid-phase refolding of human glucagon-like peptide-1 using recombinant Escherichia coli.

  2011cites this paper
• GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies

  2011cites this paper
• Effets bénéfiques de l'oxytocine sur la prise alimentaire et le métabolisme des lipides chez le rongeur normal et dans un modèle d'obésité induite par la diète

  2011cites this paper
• Type 2 Diabetes Mellitus: A Possible Surgically Reversible Intestinal Dysfunction

  2011cites this paper
• Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor

  2011cites this paper
• Expression of mRNA for proglucagon and glucagon-like peptide-2 (GLP-2) receptor in the ruminant gastrointestinal tract and the influence of energy intake.

  2010cites this paper
• Hormonal interactions between gut and brain.

  2010cites this paper
• Glucagon and glucagon-like peptides 1 and 2.

  2010cites this paper
• The Incretins and Pancreatic β-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus

  2010cites this paper
• Die Wirkung des Dipeptidylpeptidase-4-Inhibitors Vildagliptin auf die Magenentleerung, die Glykämie und den Glukosestoffwechsel bei Patienten mit Diabetes mellitus Typ 2

  2010cites this paper
• The Role of Incretins in Insulin Secretion

  2010cites this paper
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.

  2010influential citation
• Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

  2010cites this paper
• Incretin hormones and beta cell function in chronic pancreatitis.

  2010cites this paper
• Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.

  2009cites this paper
• Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

  2009cites this paper
• Treatment of type 2 diabetes with glucagon‐like peptide‐1 receptor agonists

  2009cites this paper
• Incretin-based therapy of type 2 diabetes mellitus.

  2009cites this paper
• Receptor‐mediated activation of gastric vagal afferents by glucagon‐like peptide‐1 in the rat

  2009cites this paper
• Stoffwechsel-Kontrolle bei intensivpflichtigen Patienten mit Typ 2 Diabetes durch Gabe von Glucagon-like Peptide 1

  2009cites this paper
• IDENTIFICATION AND CHARA CTERIZATION OF THE GLUCAGON-LIKE PEPTIDE-2 HORMONAL SYSTEM IN RUMINANTS

  2009cites this paper
• Elevated basal and post-feed glucagon-like peptide 1 (GLP-1) concentrations in the neonatal period.

  2009cites this paper
• Incretins and Regulation of Insulin Secretion

  2008cites this paper
• Pharmacotherapy of Diabetes

  2007cites this paper
• Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.

  2007cites this paper
• The physiology of glucagon-like peptide 1.

  2007cites this paper
• The Incretin Modulators – Incretin Mimetics (GLP-1 Receptor Agonists) and Incretin Enhancers (DPP-4 Inhibitors)

  2007influential citation
• Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes.

  2007cites this paper
• Co-localisation of the Kir 6 . 2 / SUR 1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes

  2007cites this paper
• Meal-stimulated glucagon release is associated with postprandial blood glucose level and does not interfere with glycemic control in children and adolescents with new-onset type 1 diabetes.

  2007cites this paper
• GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

  2006cites this paper
• Incretins and the development of type 2 diabetes

  2006cites this paper